The Achilles heel of BCG - 20/08/11
Tel.: +1 970 491 5777; fax: +1 970 491 5125.Summary |
There have been multiple explanations put forward to try to explain the variable efficacy of the BCG vaccine. Here I propose the new hypothesis that the primary flaw of BCG is its inability to effectively establish a population of central memory T cells. Instead, the vaccine establishes immunity represented by effector memory T cells; these distribute in the lungs and may protect humans for 10–15 years but are gradually lost. With no central memory response to compensate, the individual loses any further resistance to tuberculosis. This may have serious implications for vaccine design, given the emphasis on developing recombinant forms of BCG.
Le texte complet de cet article est disponible en PDF.Keywords : Tuberculosis, BCG, Vaccine, Memory T cells
Vol 90 - N° 6
P. 329-332 - novembre 2010 Retour au numéro
Article précédent
- Editorial Board
- Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors
- Mudassar Altaf, Christopher H. Miller, David S. Bellows, Ronan O’Toole
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?